Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Promedior Inc.

This article was originally published in Start Up

Executive Summary

In normal healing, monocytes differentiate into both regulatory macrophages and profibrotic cells known as M2 macrophages and fibrocytes. During fibrosis, that balance is upset and differentiation favors profibrotic cells. Promedior Inc. is developing pentraxin therapeutics designed to control the initiation and progression of fibrosis across a variety of tissues and organ systems.

Related Content

Start-Up Previews


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts